Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Smithy

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Cancer Cell|November 1, 2024
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanomaJames W Smithy, Michael A Postow
Journal of Surgical Oncology|April 8, 2021
Pancreas cancer: Therapeutic trials in metastatic diseaseJames W Smithy, Eileen M O'Reilly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 BlockadeJames W Smithy, Jason J Luke
Lancet (London, England)|September 13, 2022
Adjuvant checkpoint blockade following complete local therapy for melanoma metastasesJames W Smithy, Michael A Postow
Cancer Discovery|March 8, 2022
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?James W Smithy, Alexander N Shoushtari
Cancer Journal (Sudbury, Mass.)|March 25, 2024
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic DiseaseJames W Smithy, Paul B Chapman
Transplantation and Cellular Therapy|March 15, 2025
The Clinical TIL Experience in Melanoma: Past, Present, FutureJames W Smithy, Adam J Schoenfeld, Allison Betof Warner
JAMA Internal Medicine|July 30, 2014
Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional studyJames W Smithy, Nicholas S Downing, Joseph S Ross
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse EventsJames W Smithy, David M Faleck, Michael A Postow
Journal for Immunotherapy of Cancer|November 28, 2022
Ensuring equity in the era of HLA-restricted cancer therapeuticsJames W Smithy, Amanda Blouin, Lisa C Diamond, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Cancer Cell|November 1, 2024
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanomaJames W Smithy, Michael A Postow
Journal of Surgical Oncology|April 8, 2021
Pancreas cancer: Therapeutic trials in metastatic diseaseJames W Smithy, Eileen M O'Reilly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 BlockadeJames W Smithy, Jason J Luke
Lancet (London, England)|September 13, 2022
Adjuvant checkpoint blockade following complete local therapy for melanoma metastasesJames W Smithy, Michael A Postow
Cancer Discovery|March 8, 2022
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?James W Smithy, Alexander N Shoushtari
Cancer Journal (Sudbury, Mass.)|March 25, 2024
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic DiseaseJames W Smithy, Paul B Chapman
Transplantation and Cellular Therapy|March 15, 2025
The Clinical TIL Experience in Melanoma: Past, Present, FutureJames W Smithy, Adam J Schoenfeld, Allison Betof Warner
JAMA Internal Medicine|July 30, 2014
Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional studyJames W Smithy, Nicholas S Downing, Joseph S Ross
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse EventsJames W Smithy, David M Faleck, Michael A Postow
Journal for Immunotherapy of Cancer|November 28, 2022
Ensuring equity in the era of HLA-restricted cancer therapeuticsJames W Smithy, Amanda Blouin, Lisa C Diamond, et al.
Pageof 4